Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Chris Caldwell of United Renewables in Conversation with Venture Capitalist Amory Poulden DOUGLAS, Isle of Man, July 20, 2023 (GLOBE NEWSWIRE) -- As the sustainability revolution sweeps through...
-
Treatment with NE3107 led to >50% reductions in DNA methylation of 400 CpGs* and some in a manner that was significantly correlated to observed clinical improvements in cognition and various...
-
CARSON CITY, Nev., July 10, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of...
-
SYDNEY , June 30, 2023 (GLOBE NEWSWIRE) -- Pepe 2.0, the reincarnated version of the beloved cryptocurrency, is here to rectify past mistakes and revolutionize the world of digital assets. With a...
-
WASHINGTON, June 29, 2023 (GLOBE NEWSWIRE) -- Key Highlights Pending home sales dropped in May, down 2.7% from April.Month over month, contract signings decreased in three U.S. regions but...
-
VANCOUVER, BC, CANADA, June 29, 2023 (GLOBE NEWSWIRE) -- Victory’s Exploration Team advances its key properties with one drill program just completed and three work programs planned and/or...
-
TORONTO, June 19, 2023 (GLOBE NEWSWIRE) -- Platinex Inc. (CSE: PTX) (OTCQB: PANXF, Frankfurt: 9PX) (“Platinex” or the “Company”) is pleased to provide an update on its exploration activities and...
-
CHERRY HILL, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- Walter Lynch is a water industry veteran, having led the water and waste sectors through seasons of transformation as CEO of American Water, the...
-
VANCOUVER, British Columbia, June 12, 2023 (GLOBE NEWSWIRE) -- Trailbreaker Resources Ltd. (TBK.V) (“Trailbreaker” or “the Company”) is pleased to announce the signing of an option agreement with...
-
- Data updates at EAACI 2023 continue to position barzolvolimab as a potential best-in-class addition to a historically limited treatment landscape -- At week 24, 55% of all patients with CSU in the...